Cancer immunotherapy provides unprecedented long-term antitumor activity in some patients, however the majority of patients with advanced cancers only experience short-term remission. To achieve better outcomes for everyone will require a mechanistic understanding of response, and resistance, to these therapies, including immune inhibitory checkpoint blockade and T-cell engineering. These insights will provide rationale for how to best combine these therapeutic approaches for sustained clinical success.
In this virtual meeting we will tackle many of these unanswered questions in the field, including: How do cancers adapt and resist T cell attack? Can we better understand the tumor microenvironment to pave the way for new approaches to immunotherapy? What is the rationale behind immune-oncology (IO) combinations in clinical testing?
Oxford Global’s Immuno Series features 2 outstanding programmes consisting of key discussion topics in Immuno-Oncology, Autoimmunity, Immunology and Inflammation, enabling attendees to gain actionable insights into the approaches impacting this field from the leading immunotherapy experts.
Join the 5th Annual Advances in Immuno-Oncology Congress on 24-25 August and network with 350+ leaders at the forefront of research into the immune system. Connect with experts from pharma, biotech and academia working on the delivery of innovative immunotherapies.
The ESMO Congress is the most influential oncology platform in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world. ESMO Congress 2020 will present the very latest advances in oncology and translate science into better cancer patient care.
The ESMO Congress 2020 programme will be developed by a committee composed of more than 300 international experts under the leadership of Scientific Chair Prof John Haanen, NKI Amsterdam, Netherlands, a leading expert in the field of immunotherapy.
The Cancer Research Institute (CRI), the European Network for Cancer Immunotherapy (ENCI), and the American Association for Cancer Research (AACR) are proud to present the Sixth International Cancer lmmunotherapy Conference.
The 2020 meeting will be held at the New York Hilton Midtown in New York City from September 14-17, 2020. The program will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.
NEW DATE: October 2-3, 2020 Virtual event
The 7th Immunotherapy of Cancer Conference (ITOC7) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.
ITOC7 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Society for Immunotherapy of Cancer (SITC), the German Cancer Consortium (DKTK) as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.
The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.
The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year to ensure the health and safety of program attendees and their patients, and in celebration of the society’s 35th anniversary, all SITC members are invited to register for FREE!
The conference includes cutting-edge research presented by experts in the field, oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including networking opportunities. Attendees participate in a variety of basic-, translational- and clinical-focused concurrent sessions and are updated about national and international initiatives from academia, government and industry, and other important SITC projects.
NEW DATE: The 8th
Antibody Industrial Symposium AIS2020 jointly organized by the scientific society LabEx MAbImprove
and MabDesign, the French association of the Immunotherapy Industrial sector, will be held the 23 and 24 of November 2020 in Montpellier. This year edition will focus on a major theme chosen by the Scientific Advisory Board: “Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases”. It includes keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies.
Moreover, the program will allow opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering.
ACIR readers get a 15% discount with the code ACIR15.
The focus of the IRCI symposium allows prominent scientists and clinicians to present their recent data in the multidisciplinary area of immunology in cancer and/or infectious diseases. As in our prior 1st IRCI symposium in 2017, our goal is to keep the number of participants limited thereby driving increased discussion between leaders in the field and attendees, thus strengthening as well as defining immunological research and curative therapies in the near future.
The IRCI meeting is organized by researchers from two leading centers in Lyon, the CIRI and CRCL. The first edition gathered more than 340 people from all around the world. This 2021 edition will highlight the recent discoveries in innate and adaptive immunity, immuno-metabolism; immunotherapy and (epi)genetics.
The Leipzig Immune ONcology (LION) Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology. The annual meeting is organized by the Fraunhofer Institute for Cell Therapy and Immunology and the University Cancer Center of the University Hospital Leipzig.